New York, New York (PRWEB) December 31, 2013
Hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/ ) filed after the 2012 recall of GranuFlo and NaturaLyte dialysis concentrates continue to move forward in a federal multidistrict litigation underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the proceeding’s first Status Conference of the new year will be held on February 3, 2014. So far, more than 430 lawsuits have been filed in the proceeding on behalf of individuals who allegedly suffered serious and catastrophic heart problems related to the GranuFlo recall.( In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“We are representing a number of clients in GranuFlo lawsuits, and are looking forward to more progress in this proceeding as we enter the new year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects related to the GranuFlo recall within 72 hours of a dialysis treatment involving the use of GranuFlo of NaturaLyte.
The GranuFlo recall originated with the issuance of an Urgent Product Notification in March 2012 by Fresenius Medical Care, the manufacturer of GranuFlo and NaturaLyte. The notice warned that inappropriate dosing of the products could raise the amount of bicarbonate in a patient’s blood high enough to cause metabolic alkalosis. This condition increases the risk that dialysis patients may suffer heart attacks, strokes, sudden cardiac death, and other serious heart problems during or shortly after treatments. The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to the Urgent Product Notification, which indicates that GranuFlo and NaturaLyte posed a risk of serious injury and death.
According to a New York Times report from June 2012, the FDA launched an investigation of Fresenius Medical Care after it became aware of an internal memo circulated by the company to its in-network dialysis clinics in November 2011 that detailed the dosage issues associated with GranuFlo and NaturaLyte. The FDA is questioning Fresenius’ motivation for not sending a similar warning to dozens of other dialysis clinics outside of its network at that time.*
According to court documents, all of the dialysis lawsuits pending in the District of Massachusetts allege that Fresenius failed to provide adequate warnings regarding the risks associated with GranuFlo and NaturaLyte. Plaintiffs also claim the company continued to aggressively market the products even once it became aware of those risks.
Victims of serious heart side effects allegedly related to the GranuFlo recall may be entitled to compensation from Fresenius Medical Care. To learn more about filing a GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP